Japan· JP-8115003X1011
ジヒドロコデインリン酸塩
A dihydrocodeine product containing ジヒドロコデインリン酸塩, registered in Japan, on the national reimbursement list. The same ATC class is registered in 9 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Dihydrocodeine is registered in 9 of 19 countries.
Countries holding a registration under ATC N02AA08 (dihydrocodeine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 5 of them publish a price we can compare per daily dose
Dihydrocodeine · ATC N02AA08
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Germany
- Ireland
- Japan
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ジヒドロコデインリン酸塩
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- N02AA08
- ATC class
- Dihydrocodeine
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
165 interactions on record for dihydrocodeine.
Graded by severity as the source publishes them — 16 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dihydrocodeine · interactions on record
165 records
- 16 severe
- 147 moderate
Most severe, free to view
- AlvimopanA06AH02severe
- ChlorphenesinD01AE07severe
- ChlorphenesinG01AX21severe
- ProcarbazineL01XB01severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N02AA08
Dihydrocodeine, as other registers publish it.
- United KingdomDF 118 Forte 40mg tabletsMartindale Pharmaceuticals Ltd
- NorwayDHC continusNapp Pharmaceuticals Limited
- CzechiaDHC CONTINUSEnnogen Healthcare (Europe) Limited, Dublin
- CzechiaDHC CONTINUSEnnogen Healthcare (Europe) Limited, Dublin
- CzechiaDHC CONTINUSEnnogen Healthcare (Europe) Limited, Dublin
- CzechiaDHC CONTINUSEnnogen Healthcare (Europe) Limited, Dublin
- CzechiaDHC CONTINUSEnnogen Healthcare (Europe) Limited, Dublin
- CzechiaDHC CONTINUSEnnogen Healthcare (Europe) Limited, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e6874419-b4cf-418e-b17e-0da92e9a790b GET /v1/drugs/e6874419-b4cf-418e-b17e-0da92e9a790b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１ｇ",
"marks": "局 麻",
"source": "mhlw",
"remarks": null,
"yj_code": "8115003X1011",
"category": "内用薬",
"price_yen": null,
"generic_name": "ジヒドロコデインリン酸塩",
"product_name_jp": null,
"therapeutic_class": "8115",
"transitional_expiry": null
}See everything about dihydrocodeine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.